Leerink Partnrs Weighs in on Galecto FY2029 Earnings

Galecto, Inc. (NASDAQ:GLTO) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for shares of Galecto in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($4.14) for the year. The consensus estimate for Galecto’s current full-year earnings is ($15.59) per share.

Separately, Oppenheimer upped their price target on Galecto from $9.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th.

Galecto Trading Down 8.1 %

GLTO stock opened at $4.55 on Friday. The business’s 50-day moving average is $5.18 and its 200 day moving average is $8.42. Galecto has a 12-month low of $4.40 and a 12-month high of $23.50. The stock has a market cap of $5.99 million, a price-to-earnings ratio of -0.24 and a beta of 1.17.

About Galecto

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.